A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ulka N. Vaishampayan, Vivek Narayan, David Wise, Joshua Michael Lang, Benjamin H Lowentritt, Begona Mellado, Joan Carles, M Isabel Sáez, Wassim Abida, Mary-Ellen Taplin, Arun Azad, Karrie Wang, Olena Barbash, Geraldine Ferron-Brady, Doug Fecteau, Ahmed Hussein Khaled, Arindam Dhar, Johann S. De Bono
Institutions: The Barbara Ann Karmanos Cancer Institute, Abramson Cancer Center, NYU Langone Health, New York University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Chesapeake Urology Associates, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Spanish National Cancer Research Centre, Instituto de Investigación Biomédica de Málaga, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Monash University, GlaxoSmithKline (United States), Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2789986513